dm+d

704263006

Articles

Evidence for use of siltuximab or anakinra as second line therapies (after failure of tocilizumab) for Cytokine Release Syndrome following use of Chimeric Antigen Receptor T-cell (CAR-T) therapy

10 May 2019CAR-T therapy often causes cytokine release syndrome (CRS) which is treated with tocilizumab as first-line therapy. Tocilizumab is licensed for this indication but in some…
Search Articles

Refrigerated Storage

SylvantEusa Pharma UK

Eusa Pharma UK
Sylvant
100mg and 400mg powder for concentrate for solution for infusion

In the event of an inadvertent temperature excursion the following data may be used:
In-house stability data shows that following exposure to 25°C for 9 days (cumulative), there was no observed adverse effect on the biochemical or physical properties of the product.
Following exposure to -18°C for 18 days (cumulative), there was no observed adverse effect on the biochemical or physical properties of the product.

Please also refer to the manufacturer’s product literature for recommended storage information at https://www.medicines.org.uk

Contact Eusa Pharma UK in cases where additional stability information is required. Refer to the current BNF for company contact details.

No- if exposed to above
Yes- if exposed to above
15 November 2021
London MI Service